AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:00:00Z
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Income before tax | 11.70M | 15.12M | 11.09M | 11.39M | 10.56M |
| Minority interest | - | - | - | - | - |
| Net income | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M |
| Selling general administrative | 34.72M | 24.96M | 20.57M | 16.36M | 11.80M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 47.95M | 43.08M | 35.87M | 30.94M | 24.94M |
| Reconciled depreciation | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M |
| Ebit | 4.88M | 11.34M | 7.86M | 8.89M | 10.65M |
| Ebitda | 8.72M | 14.91M | 11.45M | 11.85M | 13.43M |
| Depreciation and amortization | 3.84M | 3.57M | 3.59M | 2.96M | 2.78M |
| Non operating income net other | - | 0.20M | -0.14600M | -0.21813M | 0.02M |
| Operating income | 8.72M | 11.34M | 7.86M | 8.89M | 10.65M |
| Other operating expenses | 50.85M | 38.99M | 35.21M | 29.98M | 23.32M |
| Interest expense | 0.00000M | 0.72M | 0.02M | 2.50M | 0.11M |
| Tax provision | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M |
| Interest income | 4.13M | 0.72M | 0.20M | 0.03M | 0.03M |
| Net interest income | 4.13M | 0.72M | 0.18M | 0.03M | -0.07556M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M |
| Total revenue | 59.58M | 53.91M | 46.47M | 41.59M | 33.97M |
| Total operating expenses | 39.22M | 28.17M | 24.61M | 19.33M | 14.30M |
| Cost of revenue | 11.63M | 10.82M | 10.60M | 10.65M | 9.03M |
| Total other income expense net | 2.97M | 3.78M | 3.22M | 2.50M | -0.09225M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M |
| Net income applicable to common shares | - | 12.48M | 9.78M | 9.33M | 8.58M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Total assets | 186.10M | 188.38M | 179.98M | 168.42M | 45.20M |
| Intangible assets | 32.85M | 26.18M | 24.58M | 24.99M | 13.27M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.90M | 3.38M | 1.70M | 1.60M | 0.70M |
| Total liab | 16.07M | 10.13M | 14.20M | 12.39M | 7.52M |
| Total stockholder equity | 170.03M | 178.25M | 165.78M | 156.04M | 37.68M |
| Deferred long term liab | - | 1.46M | 1.73M | 2.35M | 2.73M |
| Other current liab | 8.30M | 4.18M | 10.15M | 4.25M | 3.40M |
| Common stock | 144.97M | 138.51M | 133.42M | 0.00993M | 0.00760M |
| Capital stock | 144.97M | 138.51M | 133.42M | 0.00993M | 0.00760M |
| Retained earnings | 25.20M | 40.04M | 32.41M | 27.44M | 22.35M |
| Other liab | - | 1.46M | 1.73M | 6.42M | 2.73M |
| Good will | 19.10M | 12.92M | 12.92M | 12.92M | 10.39M |
| Other assets | - | 0.44M | 0.05M | 18.96M | 0.04M |
| Cash | 57.52M | 51.57M | 36.98M | 49.21M | 11.44M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 11.99M | 7.74M | 11.57M | 5.50M | 4.78M |
| Current deferred revenue | 3.10M | 2.86M | 0.65M | 0.44M | 1.18M |
| Net debt | -56.32600M | -50.16300M | -35.70600M | -48.28054M | -11.43550M |
| Short term debt | 0.44M | 0.46M | 0.38M | 0.46M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.20M | 1.40M | 1.28M | 0.93M | - |
| Other stockholder equity | - | -0.30800M | 133.42M | 128.53M | 15.32M |
| Property plant equipment | - | 2.05M | 3.11M | 0.44M | 0.34M |
| Total current assets | 130.37M | 146.79M | 139.31M | 129.09M | 21.17M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 139.15M | 128.28M | 118.12M | 14.03M |
| Short term investments | 57.94M | 76.67M | 86.62M | 66.80M | - |
| Net receivables | 10.20M | 13.79M | 13.00M | 10.52M | 8.26M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.80M | 1.39M | 1.01M | 0.97M | 0.77M |
| Accounts payable | 0.14M | 0.23M | 0.39M | 0.35M | 0.20M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.14100M | -0.30800M | -0.04300M | 0.06M | -1.08313M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 138.51M | - | 0.00993M | 0.00760M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 40.04M | 32.41M | 27.44M | 22.35M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.42M | -1.01700M | 0.05M | 0.05M | 0.04M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 55.73M | 41.59M | 40.66M | 39.33M | 24.03M |
| Capital lease obligations | 1.20M | 1.40M | 1.28M | 0.93M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Investments | 7.37M | 8.28M | -22.16600M | -76.72028M | -1.95574M |
| Change to liabilities | - | 2.05M | 0.25M | -0.49525M | 0.72M |
| Total cashflows from investing activities | - | 4.30M | -26.74200M | -75.50571M | -1.95574M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -23.26600M | -7.62200M | -4.68400M | 102.37M | -7.64788M |
| Change to operating activities | - | -0.35600M | 3.25M | -0.37518M | 0.39M |
| Net income | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M |
| Change in cash | 5.96M | 14.58M | -12.22300M | 37.77M | 2.03M |
| Begin period cash flow | 51.57M | 36.98M | 49.21M | 11.44M | 9.40M |
| End period cash flow | 57.52M | 51.57M | 36.98M | 49.21M | 11.44M |
| Total cash from operating activities | 21.86M | 17.90M | 19.20M | 10.91M | 11.64M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 107.75M | - |
| Depreciation | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M |
| Other cashflows from investing activities | - | -3.15100M | -2.94900M | 1.45M | -1.81800M |
| Dividends paid | -4.80900M | -4.84600M | -4.81100M | -4.25047M | 4.20M |
| Change to inventory | 0.91M | - | 3.15M | -0.24725M | -1.30760M |
| Change to account receivables | 4.10M | -3.93600M | -2.42900M | -2.01779M | 0.49M |
| Sale purchase of stock | -20.00000M | -20.00000M | 1.46M | 108.38M | 0.79M |
| Other cashflows from financing activities | 1.54M | -3.66700M | 0.13M | -1.13128M | -3.45083M |
| Change to netincome | - | 4.46M | 4.86M | 1.40M | 0.89M |
| Capital expenditures | 4.27M | 3.97M | 4.58M | 2.58M | 1.96M |
| Change receivables | - | -3.93600M | -2.42900M | -1.87748M | -0.76009M |
| Cash flows other operating | - | 0.44M | -0.32400M | -0.41059M | -0.54639M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 14.58M | -12.22300M | 37.77M | 2.03M |
| Change in working capital | 5.10M | -2.62000M | 0.97M | -2.78332M | -0.58296M |
| Stock based compensation | 4.83M | 3.04M | 2.75M | 1.58M | 1.08M |
| Other non cash items | 0.22M | 1.70M | 2.73M | 0.20M | 0.11M |
| Free cash flow | 17.58M | 13.93M | 14.63M | 8.33M | 9.68M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SLP Simulations Plus Inc |
-1.0 2.14% | 45.65 | 93.08 | 65.79 | 14.54 | 5.10 | 12.65 | 48.51 |
| GEHC GE HealthCare Technologies Inc. |
-0.77 0.89% | 85.95 | 22.39 | 17.33 | 1.78 | 4.79 | 2.18 | 11.79 |
| VEEV Veeva Systems Inc Class A |
-1.43 0.71% | 199.09 | 54.61 | 33.22 | 12.83 | 6.73 | 11.14 | 58.84 |
| MTHRF M3 Inc |
- -% | 14.60 | 29.72 | 25.00 | 0.05 | 4.38 | 0.04 | 0.12 |
| MTHRY M3 Inc |
-0.1199 1.98% | 5.95 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
42505 Tenth Street West, Lancaster, CA, United States, 93534-7059
| Name | Title | Year Born |
|---|---|---|
| Mr. Walter S. Woltosz M.A.S., M.S. | Co-Founder & Chairman | 1945 |
| Mr. Shawn M. O'Connor | Chief Exec. Officer | 1960 |
| Mr. John Anthony DiBella M.S. | Pres | 1980 |
| Mr. William Frederick | CFO & Sec. | 1964 |
| Dr. Brett A. Howell Ph.D. | Pres of DILIsym Services, Inc | 1984 |
| Ms. Jill Fiedler-Kelly M.S., MS | Pres of Cognigen Division | 1970 |
| Ms. Viera Lukacova Ph.D. | Chief Scientific Officer | NA |
| Dr. Bud Nelson J.D., Ph.D. | VP of Corp. Counsel & Personal Data Protection Officer | NA |
| Ms. Arlene Padron | Corp. Director of Marketing | NA |
| Ms. Lindsay Luke | Exec. Director of HR | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...